New York Marriott Marquis
1535 Broadway
New York, NY 10036

State-of-the-art cancer care continues to evolve due to advances in all aspects of patient care - including diagnosis, and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow^®, has brought together over 2,000 oncologists, hematologists, radiation oncologists, immunologists, pharmacists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 33 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 34th Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow^®, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty will continue to provide expert insights on new developments in cancer therapeutics, and provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of control and cure of cancer.

This activity is supported by educational grants from Ariad Pharmaceuticals, Inc., Astellas, AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Exelixis, Inc., Genomic Health, Inc., Incyte, Lilly, Medivation, Inc., Merck, NantHealth, Inc., Novartis Pharmaceuticals Corporation, Novocure Inc., Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Sirtex, Taiho Oncology, Inc., Takeda Oncology, Tesaro, Inc., and Teva Pharmaceuticals.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.



The CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow^® is wholly owned and operated by PER Events, LLC, an affiliate of Physicians' Education Resource^®.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 22.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 22.0 Contact Hours.

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for a maximum of 22.0 contact hours (0.22 CEUs).

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other health care professionals interested in the treatment of cancer are also invited to attend.

Upon completion of this activity, participants should be better prepared to:

• Report practice-changing results from clinical trials that impact evolving treatment paradigms in hematologic and solid tumor management
• Outline testing methods for prognostic and predictive markers that inform personalized care strategies in the treatment of cancer
• Discuss optimized chemotherapeutic, targeted, and immunotherapy strategies based on clinical trial evidence
• Describe methods to monitor efficacy and manage treatment-related adverse events in multiple lines of cancer management
• Place recent clinical trial findings in the context of evolving treatment pathways to improve care for patients with cancer